150 completed, 5 recruiting, 5 terminated, 5 unknown. 59 Phase 3, 52 Phase 1, 26 Phase 4, 14 Phase 2, 5 Not applicable.
Follow insulin degludec: new trials by email Literature Review of insulin degludec trials Research Report on insulin degludec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males UBT38006, Placebo, Insulin Degludec Injection - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 53 | 2026-06-17 | 2026-09-15 |
| Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes GZR101-80, GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) - Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 345 | 2026-04-10 | 2026-04-15 |
| Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes GZR33 Injection, Insulin Degludec Injection (Tresiba®) - Type 2 Diabetes (T2DM) | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 350 | 2026-04-07 | 2026-07-01 |
| Single-ascending Dose Study of HEC-151 Injection HEC-151 Injection, Degludec insulin, Placebo - Healthy Adult Male | Phase 1 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 81 | 2026-02-24 | 2026-09-25 |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin LY3938577, Degludec - Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | Eli Lilly and Company | 100 | 2025-10-13 | 2026-07-13 |
| Comparison Study of Insulin GZR4 With Insulin Degludec GZR4 injection - Type 2 Diabetes | Phase 1 | Recruiting | Gan and Lee Pharmaceuticals, USA | 14 | 2025-08-15 | 2025-08-28 |
| A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes SHR-3167 Injection, Insulin Degludec Injection - Type 2 Diabetes | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 55 | 2025-08-11 | 2026-04-17 |
| A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs SHR-3167, Insulin Degludec - Type 2 Diabetes Mellitus | Phase 2 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 173 | 2025-07-16 | 2025-11-18 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin GZR4, insulin degludec - Diabetes | Phase 3 | Active not recruiting | Gan & Lee Pharmaceuticals. | 620 | 2025-02-15 | 2025-11-21 |
| A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes NNC0363-1063, Placebo, Insulin degludec - Diabetes Mellitus, Type 1 | Phase 1 | Completed | Novo Nordisk A/S | 117 | 2024-11-12 | 2026-04-09 |
| A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus Degludec insulin - Type 2 Diabetic Patients | Phase 4 | Enrolling by invitation | Beijing Tsinghua Chang Gung Hospital | 170 | 2024-05-20 | 2025-04-13 |
| A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) LY3938577, Placebo, Insulin Degludec - Healthy, Type 1 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 121 | 2024-05-15 | 2026-10-06 |
| A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting Insulin icodec, Insulin degludec - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Novo Nordisk A/S | 30 | 2024-02-26 | 2026-06-08 |
| Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia Insulin Glargine, Insulin Degludec, Insulin regular - Glycemic Control, Insulin | Not applicable | Completed | Ain Shams University | 90 | 2023-12-01 | 2024-08-05 |
| A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level Insulin degludec - Diabetes Mellitus, Type 2 | Completed | Novo Nordisk A/S | 179 | 2023-11-29 | 2026-01-09 | |
| A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus LY3938577, Placebo, Insulin degludec - Healthy, Type 2 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 66 | 2023-11-17 | 2024-07-24 |
| Comparing the Safety and Efficacy of Insulin GLARGINE and DEGLUDEC in Glucocorticoid Induced HYPERGLYCEMIA in Hospitalized Patients". Degludec insulin, Glargine insulin - Glucocorticoid Induced Hyperglycemia | Phase 4 | Completed | Max Healthcare Insititute Limited | 79 | 2023-09-01 | 2026-05-20 |
| A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus GZR4 Injection, Insulin Degludec - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Gan and Lee Pharmaceuticals, USA | 179 | 2023-08-11 | 2025-01-23 |
| INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes Afrezza, insulin degludec, Rapid-acting Insulin Analog - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Mannkind Corporation | 141 | 2023-07-07 | 2024-08-09 |
| Degludec Insulin Use in Critically Ill Patients Degludec insulin - Diabetes Mellitus, Critical Illness | Not applicable | Completed | King Faisal Specialist Hospital & Research Center | 155 | 2023-05-17 | 2024-06-13 |
Showing 20 of 170. Sign in to see all of them.
Diabetes Mellitus (94) · Diabetes Mellitus, Type 2 (92) · Diabetes Mellitus, Type 1 (61) · Insulin Resistance (8) · Critical Illness (2) · Hyperglycemia (2) · Hypoglycemia (2) · Respiratory Aspiration (2) · Autoimmune Diseases (1) · Diabetic Nephropathies (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Motor Activity (1) · Renal Insufficiency (1)
Novo Nordisk A/S (99) · Eli Lilly and Company (18) · Sanofi (5) · Gan and Lee Pharmaceuticals, USA (4) · Gan & Lee Pharmaceuticals. (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Mannkind Corporation (3) · Ain Shams University (2) · Emory University (2) · Sunshine Lake Pharma Co., Ltd. (2) · Beijing Tsinghua Chang Gung Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Diasome Pharmaceuticals (1) · Elaine Chow (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1)
United States (66) · Germany (57) · China (27) · Canada (23) · Puerto Rico (23) · Japan (22) · Italy (21) · Spain (19) · United Kingdom (18) · Argentina (16) · Austria (16) · Poland (16) · Russia (16) · India (15) · France (14)
Kevin Kaiserman, MD (2) · Antonino Tuttolomondo, Professor (1) · Arthi Thirumalai, MD (1) · Chunyue Hao (1)
PMID 23130654, PMID 24170235, PMID 26232910, PMID 26121451, PMID 25581159, PMID 26484727, PMID 26663320, PMID 24812526, PMID 25081590, PMID 36106652, PMID 40465144, PMID 28946756, PMID 40186685, PMID 42814374, PMID 22594461, PMID 24622318, PMID 25998481, PMID 26894800, PMID 28210866, PMID 28282219, PMID 28672316, PMID 30097995, PMID 30362250, PMID 31865758, PMID 33166419, PMID 33595901, PMID 35044568, PMID 38035641, PMID 39368488, PMID 39963952, PMID 41591636, PMID 19017758, PMID 20091571, PMID 21228246, PMID 21270174, PMID 21396703, PMID 22150786, PMID 22521071, PMID 22521072, PMID 22726241, PMID 23340894, PMID 23393185, PMID 23435159, PMID 23577643, PMID 23715753, PMID 23749405, PMID 23812875, PMID 23952326, PMID 24057153, PMID 24163264
2009 (16), 2008 (10), 2015 (6), 2016 (3), 2017 (3), 2019 (3), 2014 (2), 2018 (2), 2023 (2), 2005 (1)